MGV354治疗高眼压或青光眼的随机对照I/II期研究
该双盲随机赋形剂对照研究评估局部用可溶性鸟苷酸环化酶激活剂MGV354治疗高眼压或青光眼的安全性及降眼压疗效。第3部分中,MGV354 0.1%组第8天日间平均眼压较基线变化-0.6 mmHg,赋形剂组-1.1 mmHg,置信区间-0.7至1.7,主要结局指标未显示统计学显著差异。最常见不良事件为结膜充血和眼充血。
要点
- MGV354 0.1%降眼压效果与赋形剂相比无统计学显著差异。
- 第3部分第8天日间平均眼压变化:MGV354组-0.6 mmHg,赋形剂组-1.1 mmHg。
- 最常见不良事件为结膜充血和眼充血,与药理学作用一致。
核心结论
- MGV354 0.1%基于主要结局指标在降眼压方面与赋形剂相比无统计学显著效果。
- MGV354产生与药理学作用一致的眼充血。
研究设计与样本
- 双盲、随机、赋形剂对照研究,分3部分。
- 第1部分在32名健康志愿者中评估安全性和耐受性以确定最大耐受剂量。
- 第2部分在16名高眼压或青光眼患者中评估安全性和耐受性。
- 第3部分为多中心试验,在50名上午8时眼压至少24 mmHg的患者中评估最大耐受剂量每晚给药1周的降眼压疗效。
- 主要结局指标为第8天日间平均眼压与基线比较。
主要发现
- 第3部分中,MGV354组第8天日间平均眼压较基线变化-0.6 mmHg,赋形剂组-1.1 mmHg,置信区间-0.7至1.7。
- MGV354给药后最常见不良事件为结膜充血和眼充血。
关键数值与推荐
- 第3部分患者入选标准为上午8时眼压至少24 mmHg。
- 主要结局指标为第8天日间平均眼压较基线变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the clinical safety, tolerability, and efficacy of topically administered MGV354, a soluble guanylate cyclase (sGC) activator, in patients with ocular hypertension (OH) or glaucoma. DESIGN: Double-masked, randomized, and vehicle-controlled study. METHODS: Parts 1 and 2 evaluated safety and tolerability to identify the maximum tolerated dose (MTD) of once-daily MGV354 in 32 healthy volunteers (Part 1) and 16 patients with OH or glaucoma (Part 2) at a single clinical site. Part 3 was a multisite trial that evaluated intraocular pressure (IOP)-lowering efficacy of the MTD administered nightly for 1 week in 50 patients with minimum IOP of 24 mm Hg at 8 AM, with a main outcome measure of mean diurnal IOP at day 8 compared to baseline (ClinicalTrials.govNCT02743780). RESULTS: There was no difference in favor of MGV354 for IOP lowering; change from baseline to day 8 in mean diurnal IOP was -0.6 mm Hg for MGV354-treated patients and -1.1 mm Hg for vehicle-treated patients in Part 3, with a confidence interval of -0.7 to 1.7. The most common adverse events reported after MGV354 administration were conjunctival and ocular hyperemia. CONCLUSIONS: Overall, MGV354 0.1% demonstrated no statistically significant effect compared to vehicle in lowering IOP based on the study's main outcome measure. MGV354 produced ocular hyperemia consistent with its pharmacology.
引用
- Stacy R, Huttner K, Watts J, et al. A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma. Am J Ophthalmol. 2018. PMID: 29802818. doi:10.1016/j.ajo.2018.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。